(Although … you were nominally the industry representative in the group. So wasn’t the coffee your responsibility?!?)
(Although … you were nominally the industry representative in the group. So wasn’t the coffee your responsibility?!?)
See you all in Stockholm next year #ESTRO25
See you all in Stockholm next year #ESTRO25
We conducted a prospective, longitudinal multicentre study alongside a clinical trial, asking rectal cancer patients undergoing definitive RT to help us understand their treatment preferences
#ESTRO25 #RadOnc
Here's our poster, a DCE on preferences for non-surgical rectal cancer treatment. We found:
- patients accepted more toxicity for a greater chance of cure
- long-term side effects more important than short-term
- preferences stable pre/post-treatment
Seeing an RT planning & evaluation solution for #reirradiation that I’ve helped develop in its (nearly) final version. Amazing work by @raysearchlabs.bsky.social @solstina.bsky.social @crukradnetleeds.bsky.social & colleagues.
Probably highlight of #ESTRO25 so far for me 😍
🔹Chuck Mayo: #medphys-led workflows
🔹Søren Bentzen: #radbio
🔹Marija Popovic: dose accumulation
🔹Lone Hoffmann: reRT trial design & QA
bsky.app/profile/canc...
No other scientific meeting has this high level of #radonc trial & research!
Short course RT vs chemorad for organ preservation in early stage rectal cancer
61% vs 80% TME-free survival at 12 months ➡️ More organ preservation with long-course chemorad!
#radonc #rectalcancer
bsky.app/profile/canc...
No other scientific meeting has this high level of #radonc trial & research!